Author:
Bay Jacques-Olivier,Bouleuc Carole,Firmin Nelly,Gandemer Virginie,Magne Nicolas,Orbach Daniel,Penel Nicolas,Rodrigues Manuel,Thiery-Vuillemin Antoine,Wislez Marie,L’Allemain Gilles,Sabatier Renaud,Robert Jacques
Subject
Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine
Reference57 articles.
1. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer;Tutt;N Engl J Med,2021
2. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer;Colombo;N Engl J Med,2021
3. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial;Cortes;Lancet,2020
4. LBA1 - Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study;Cortés;Ann Oncol,2021
5. Makker V, Colombo N, Herráez AC, et al. A multicenter, open-label, randomized, phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician's choice in patients with advanced endometrial cancer. Gynecol Oncol 2021;162:S4. [ISSN: 0090-8258].